AN2 Therapeutics | IPO Presentation Deck | 27 slides

AN2 Therapeutics · 2022-03
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

27
every slide · same image gating as the playbook
01
Slide 1
The slide uses a global map background to imply the scale of the mission.inspire_vision
Open slide detailLoop · Golden Circle
02
other
Open slide detailLoop · Golden Circle
03
plan_implementation
Open slide detailLoop · Golden Circle
04
transition
Open slide detailLoop · Golden Circle
05
other
Open slide detailBeat · TeamLoop · Golden Circle
06
The slide uses a split-layout with a company mission statement on the left and product-specific details on the right.summarize
Open slide detailLoop · Golden Circle
07
The slide highlights the lineage of the boron chemistry platform and the transition of assets from Anacor/Pfizer to AN2 Therapeutics.cite_precedent
Open slide detailLoop · Golden Circle
08
The slide uses a timeline-based roadmap structure to communicate clinical trial progress.plan_implementation
Open slide detailLoop · Golden Circle
09
front_matter
Open slide detailLoop · Golden Circle
10
frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
11
Uses a Venn/concentric circle diagram to illustrate market segmentation.size_opportunity
Open slide detailBeat · ProblemLoop · Cost Of Inaction
12
The slide uses a process flow to show the progression from treatment-naïve to refractory patients.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
13
Includes boxed warning information for a competitor/reference drug.cite_precedent
Open slide detailLoop · Golden Circle
14
Scientific diagram showing molecular binding interaction.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
15
MIC = Minimum Inhibitory Concentration. Data shows Epetraborole has lower MIC values compared to standard treatments.compare_peers
Open slide detailBeat · SolutionLoop · Golden Circle
16
The chart highlights statistical significance between EBO doses and the CLR control.show_traction
Open slide detailLoop · Golden Circle
17
EBO = epetraborole, SoC = standard of care (clarithromycin, ethambutol, rifabutin).analyze_data
Open slide detailLoop · Golden Circle
18
Includes a timeline diagram of the study design and key clinical findings.show_traction
Open slide detailLoop · Golden Circle
19
The slide highlights the drug's targeted delivery to the site of infection (alveolar macrophages).show_traction
Open slide detailLoop · Golden Circle
20
The slide outlines a seamless trial design with specific patient counts and milestones.plan_implementation
Open slide detailLoop · Golden Circle
21
Uses a concentric circle diagram to represent market segments and a map to show geographic reach.plan_implementation
Open slide detailLoop · Golden Circle
22
The table uses checkmarks and X marks to highlight competitive advantages of EBO.compare_peers
Open slide detailLoop · Golden Circle
23
QIDP = Qualified Infectious Disease Product Designationestablish_context
Open slide detailLoop · Golden Circle
24
Includes a timeline of clinical trials and a list of key investors.show_traction
Open slide detailLoop · Golden Circle
25
The slide highlights a focus on melioidosis and lists key research and funding partners.inspire_vision
Open slide detailLoop · Golden Circle
26
The slide uses a split-layout with a company mission statement on the left and product details on the right.summarize
Open slide detailLoop · Golden Circle
27
front_matter
Open slide detailLoop · Golden Circle